Cleantech Solutions International Inc(NASDAQ:CLNT) trended 21.41% higher to end last trading session at $3.80 after ranging between $3.74 and $4.66. The company posted fourth quarter adjusted profit of $0.98 per share after the close Thursday. Sales rose 28.3% to $17.6 million from $13.7 million.
A quick look on this stock’s price history reveals beta used to measure the volatility or systematic risk in comparison to the market as a whole was 2.07 and the percentage change in the price over the past 52 weeks remained at -92.89%. The price range in those 52 weeks had a best score of $36.90 on Mar 30, 2011while lowest level during that period was $2.00on Nov 16, 2011.
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) ranged in price between $1.65-$1.98 and gained 13.86% to close at $1.89, seemingly on expectation that it can benefit from the New Bird Flu Outbreak.
The stock moved up 33.10% in this year and its price history showed that most recently beta was at 2.54.Overall during the last 12 months, the percentage change in the price was -51.91%, hitting the highest of $4.95 on Oct 22, 2012while lowest level in that period was $1.08 on Nov 16, 2012.
Mattson Technology, Inc.(NASDAQ:MTSN) ranged in price from $1.40 to $1.61 in the last session and closed 10.64% higher to $1.56. The company today disclosed that it has signed a three-year revolving credit facility for $25 million with Silicon Valley Bank, which is a part of SVB Financial Group (NASDAQ: SIVB). Upon closing, the Company has been given a loan of $10 million with an annual interest rate of 4.75 percent.
Its shares gained 85.71% so far in 2013. The stock most recently had a beta value at 2.98 and the percentage change in the price over the last fifty two weeks remained at -32.47%. The price range in that 1-year period had a best hit of $2.65 on Apr 26, 2012 while lowest level in the same period was $0.70on Nov 19, 2012.
Cytokinetics, Inc.(NASDAQ:CYTK) stock sold in a range of $1.17 to $1.29 before ending 4.24% higher to settle at $1.23. The company declared Monday it has received grant from Families of Spinal Muscular Atrophy (FSMA) to get support in preclinical research on muscle function in a mouse model of spinal muscular atrophy (SMA) to be conducted with the company`s fast skeletal muscle troponin activator, tirasemtiv.
So far, the share price of this stock jumped 86.36% in this year and stock’s price history revealed that beta was maintained at 1.81 and the percentage change in the price over the last fifty two weeks remained as 7.89%.
Royale Energy, Inc.(NASDAQ:ROYL) ranged in price from $2.67 to $3.10 in the last session and closed 1.02% higher to $2.98 after declaring a potential joint venture worth $43M. Its shares gained 15.50% so far in 2013.
The stock most recently had a beta value at 1.45 and the percentage change in the price over the last fifty two weeks remained at -40.76%. The price range in that 1-year period had a best hit of $5.33 on Apr 13, 2012while lowest level in the same period was $1.70 on Mar 7, 2013.